As mentioned above, D-PDMP, an inhibitor of glucosylceramide synthase and lactosylceramide synthase activity, decreased GSL load and inhibited cardiac hypertrophy in a dose-dependent manner [16,17]. This evidence concerns the gene B4GALT5 and cardiac hypertrophy.